I don't think the labs are considered a part of th

Quote:

---

I don't think the labs are considered a part of the FDA trial.

---

It sure looks to me like they are part of the trial protocol:

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Link: https://clinicaltrials.gov/ct2/show/NCT04343651
Please see excerpt below.

I believe this is why Dr. BP has been so busy and running 3-shifts of 24/7 lab teams. And I'm not sure who would be in a better position to accurately test these metrics, since Dr. BP has an independent lab with a suite of companion assays customized for leronlimab.

The big questions are:

1. Does Dr. NP (or anyone else on the CytoDyn team) have access to up-to-date data on the clinical responses of each patient in each trial?

2. And if so, is there a consistent naming convention used to identify each patient's labs and clinical responses? In other words, is Dr. BP receiving a blood sample that is identified as being from "Patient #12" -- and is Dr. NP able to see the clinical response of "Patient #12"?

Quote:

---

Other Outcome Measures:
Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]

---